A novel testosterone 2% gel for the treatment of hypogonadal males.

Authors:
Adrian S Dobs
Adrian S Dobs
Johns Hopkins University School of Medicine
Baltimore | United States
Dr Paul Norwood, MD
Dr Paul Norwood, MD
University of California at San Francisco
Associate Clinical Professor of Medicine at UC San Francisco
Diabetes, cholesterol, hypertension,
Fresno, CA | United States
Julian Howell
Julian Howell
Drexel University College of Medicine
Yusong Chen
Yusong Chen
College of Chemistry and Chemical Engineering

J Androl 2012 Jul-Aug;33(4):601-7. Epub 2011 Oct 6.

Johns Hopkins University, 1830 Monument St, Suite 328, Baltimore, MD 21287, USA.

Testosterone replacement therapy (TRT) can improve the symptoms, signs, and well being of hypogonadal men by restoring serum testosterone concentrations to physiologic levels. This multicenter, open-label noncomparative trial of men with hypogonadism evaluated the pharmacokinetic profile and safety of a novel testosterone 2% gel (Fortesta™ Gel), administered once daily to the front and inner thighs at starting doses of 40 mg/d. The metered-dose delivery system allowed dose adjustments in 10-mg increments between 10 and 70 mg/d. Of the 149 patients enrolled, 138 patients (92.6%) completed the study and 129 patients (86.6%) were included in the efficacy analysis. On day 90, mean testosterone concentration (C(avg) [0-24 hours] ± SD) was 438.6 ± 162.5 ng/dL. Overall, 100 (77.5%) patients achieved serum total testosterone concentrations within the normal physiologic range (≥ 300 and ≤ 1140 ng/dL). On day 90, mean testosterone C(max) (± SD) was 827.6 ± 356.5 ng/dL. On day 90, a total of 122 patients (94.6%) had C(max) levels of 1500 ng/dL or less and 2 patients (1.6%) had values between 1800 and 2500 ng/dL. Similar results for C(avg) (0-24 hours) and C(max) were observed on day 35. All enrolled patients were included in the safety analysis. Testosterone 2% gel was generally well tolerated, with the most common adverse events (AE) being mild and moderate skin reactions. There were no serious AEs related to testosterone 2% gel. Once-daily testosterone 2% gel restored levels of testosterone in more than 75% of patients, with low risk of supraphysiologic testosterone levels. Patients may find this a suitable option for TRT because of its application site and low volume.

Download full-text PDF

Source
http://doi.wiley.com/10.2164/jandrol.111.014308
Publisher Site
http://dx.doi.org/10.2164/jandrol.111.014308DOI Listing
November 2012
21 Reads
4 Citations
2.473 Impact Factor

Publication Analysis

Top Keywords

testosterone gel
20
testosterone
11
patients
9
testosterone concentrations
8
ng/dl day
8
day testosterone
8
novel testosterone
8
gel
6
ng/dl
5
testosterone cmax
4
≤ 1140
4
1140 ng/dl
4
≥ 300
4
normal physiologic
4
physiologic range
4
range ≥
4
cmax 8276
4
300 ≤
4
day total
4
levels 1500
4

Similar Publications